MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

StatusRecruiting
PhasePhase 3
Started

Record status This record was last updated November 20, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 2024 to Mar 2025v6
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: Mar 2023 to Mar 2024v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2021 to Jun 2, 2021
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.
Trial Details
NCT Number NCT04834024
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions
(from sponsor)		 Follicular Lymphoma and Marginal Zone Lymphoma
Related terms Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular
Enrollment 168 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov